** French testing and laboratory services provider Eurofins Scientific EUFI.PA drops over 8% as it posted a lower organic growth in its BioPharma division in Q3 amid foreign exchange headwinds
** BioPharma growth "slowed sequentially" at +0.4% compared to +1.5% in the previous quarter, Jefferies says
** The broker sees the group's Q3 organic growth of +4.1% as "soft again", slightly below consensus expectations of +4.4%, while it notes weakness in North America
** Jefferies warns of FX headwinds, as Eurofins notes that if the end-Q3 USD/EUR rate prevails through FY, it would imply an about 3% revenue drag and an about 20 bps margin hit
** Shares, on track for their worst day since October 2024, fall to the bottom of the SBF 120 .SBF120 index
(Reporting by Olivier Cherfan)
((olivier.cherfan@thomsonreuters.com))